Your browser doesn't support javascript.
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States.
Peacock, W Frank; Crawford, James M; Chen, Yen-Wen Cindy; Ashton, Veronica; Campbell, Alicia K; Milentijevic, Dejan; Spyropoulos, Alex C.
  • Peacock WF; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Crawford JM; The Institute of Health Systems Science at the Feinstein Institutes for Medical Research, Manhasset, NY, USA.
  • Chen YC; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
  • Ashton V; Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
  • Campbell AK; Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
  • Milentijevic D; Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
  • Spyropoulos AC; Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
Clin Appl Thromb Hemost ; 28: 10760296221120421, 2022.
Article in English | MEDLINE | ID: covidwho-2002071
ABSTRACT
Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum® COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thromboembolism / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Clin Appl Thromb Hemost Journal subject: Vascular Diseases Year: 2022 Document Type: Article Affiliation country: 10760296221120421

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thromboembolism / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Clin Appl Thromb Hemost Journal subject: Vascular Diseases Year: 2022 Document Type: Article Affiliation country: 10760296221120421